Recent advances in understanding and treatment of Parkinson’s disease

Abstract

Though primarily a sporadic condition, Parkinson’s disease is increasingly recognized to be a multifactorial disease with a strong genetic component. At a cellular level, disruptions of protein trafficking and recycling, particularly by misfolding, accumulation, and aggregation of α-synuclein, mitochondrial dysfunction, oxidative stress, and other etiopathogenic mechanisms, have been found to result in the death of vulnerable neuronal populations and appear to drive the neurodegeneration underlying Parkinson’s disease. The improved understanding of these mechanisms has led to the development of novel pathogenesis-targeted and potentially disease-modifying therapeutic approaches in Parkinson’s disease. Until these treatments are fully developed and approved, clinicians must rely on therapies designed to improve quality of life of patients by treating various motor and non-motor symptoms of the disease.

Growing role of S100B protein as a putative therapeutic target for neurological- and nonneurological-disorders

“…Parkinson's disease (PD) is associated with the gradual loss of dopaminergic neurons in the substantia nigra of the brain responsible for the production of dopamine. As the disease progresses, other areas of the brain and nervous system degenerate causing a more intense movement disorder (Tarakad and Jankovic, 2020;Choi et al, 2020;Kumaresan and Khan, 2021).…”

Advances and applications of fluids biomarkers in diagnosis and therapeutic targets of Alzheimer's disease

“…This glycoprotein is secreted by microglia; its CSF content is positively associated with t‐Tau and p‐Tau, 90 while it is negatively correlated with AD progression 91 . YKL‐40 increases in CSF and decreases in the serum of AD patients 90,92 . YKL‐40, along with sTREM2 in young subjects, revealed better results in predicting AD 93 .…”

Emerging Therapeutic Strategies for Parkinson’s Disease and Future Prospects: A 2021 Update

“…Successful preclinical studies paved the path for a phase I trial of two anti-α-Syn vaccines, PD01A and PD03A. Both vaccinations did not exhibit major side effects at multiple doses [ 258 ].…”